Immuno-Oncology | Specialty

FDA Approves Subcutaneous Atezolizumab and Hyaluronidase-tqjs for Use in All Indications of IV Atezolizumab

September 12th 2024

The FDA has approved subcutaneous atezolizumab for use in all indications as the intravenous formulation.

Histologic Features, Risk Help Reduce Uncertainties Around Frontline Treatment Selection in RCC

September 12th 2024

Adam E. Singer, MD, PhD, details how he selects between the available TKI/IO combinations and the only dual immunotherapy regimen for patients with RCC.

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

September 5th 2024

The investigation of treatments harnessing the immune system in patients with T-cell lymphoma could lead to "a new era" of therapy for this patient population.

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC

September 4th 2024

Solange Peters, MD, PhD, discusses ways to refine checkpoint inhibition in the treatment of non–small cell lung cancer.

OncLive’s August Roundup of Key FDA Approvals in Oncology

September 4th 2024

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

Treatment Advances Underscore Need for MMR/MSI Testing in Advanced Endometrial Cancer

August 26th 2024

Bhavana Pothuri, MD, discusses real-world testing patterns for MMR/MSI status in patients with advanced endometrial cancer.

Dostarlimab Plus Chemotherapy Opens Doors Across Endometrial Cancer Subtypes

August 23rd 2024

Krishnansu S. Tewari, MD, discusses the FDA approval of dostarlimab plus chemotherapy for patients with primary advanced or recurrent endometrial cancer.

Enfortumab Vedotin Plus Pembrolizumab Approved in Canada for Advanced Bladder Cancer

August 22nd 2024

Enfortumab vedotin plus pembrolizumab has been approved by Health Canada for use in unresectable locally advanced or metastatic urothelial cancer.

ODAC Vote Aims to Introduce Clarity on Phase of Treatment Benefits in Resectable NSCLC

August 22nd 2024

John V. Heymach, MD, PhD, and Marina Chiara Garassino, MD, detail new trial design proposals for perioperative regimens in resectable NSCLC.

Dr Stiles on the FDA Approval of Perioperative Durvalumab Plus Chemo in NSCLC

August 15th 2024

Brendon M. Stiles, MD, discusses the FDA approval of perioperative durvalumab plus chemotherapy in early-stage non–small cell lung cancer.

FDA Approves Perioperative Durvalumab Plus Chemotherapy in Resectable NSCLC

August 15th 2024

The FDA has approved neoadjuvant durvalumab plus chemotherapy, followed by adjuvant durvalumab, for select resectable non–small cell lung cancer.

FDA Grants Priority Review to Durvalumab for LS-SCLC After Concurrent Chemoradiotherapy

August 15th 2024

The FDA granted priority review to durvalumab in limited-stage small cell lung cancer after platinum-based concurrent chemoradiotherapy.

Durvalumab-Based Combos Win EU Approval for Advanced/Recurrent Endometrial Cancer

August 14th 2024

Durvalumab plus chemotherapy, then durvalumab with or without olaparib, was approved in Europe for select advanced/recurrent endometrial cancer.

Immune Therapy, EGFR Inhibition Take Hold of Stage III NSCLC

August 13th 2024

Clinicians specializing in caring for patients with lung cancer discussed clinical trial updates on agents in stage III NSCLC.

Toripalimab sNDA Under Review in China for Frontline Unresectable or Metastatic Melanoma

August 13th 2024

A sNDA seeking the approval of toripalimab for frontline use in patients with unresectable or metastatic melanoma is under review by the NMPA.

Immunotherapy's Role in Improving Durability of Outcomes in Advanced Upper GI Cancers

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss how immunotherapy plus chemotherapy has improved the durability of outcomes in advanced GI cancers.

Factors for Selecting Nivolumab Plus Chemo or Nivolumab Plus Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on factors for selecting nivolumab plus chemotherapy or ipilimumab in esophageal squamous cell carcinoma.

Long-Term Data for Frontline Nivolumab Plus Chemo or Ipilimumab in Advanced ESCC

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on long-term data for nivolumab plus chemotherapy or ipilimumab in advanced esophageal squamous cell carcinoma.

A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

4-Year Data for First-Line Nivolumab Plus Chemo in Advanced Gastric/GEJ Cancer

August 13th 2024

Samuel Cytryn, MD, and David B. Zhen, MD, on 4-year data from CheckMate 649 for nivolumab plus chemotherapy in first-line advanced gastric/GEJ cancer.